乙型肝炎病毒基因突变及耐药的研究  

Study on the relationship between genic mutation and lamivudine resistance in the treatment of hepatitis B

作　　者：杜琼[1] 郭晋蓉[1] 张玲英[1] 杨明清[1] 赵珊 朱燕[3] 邓君[1] 张丁丁[1] 

机构地区：[1]四川省人民医院检验科,四川成都610072 [2]四川省成都市第八人民医院检验科,61000 [3]四川省成都市中医医院检验科,610000

出　　处：《淮海医药》2004年第2期89-90,共2页Journal of Huaihai Medicine

摘　　要：目的　研究拉咪呋啶在治疗乙型肝炎过程中乙型肝炎病毒基因突变与耐药的关系。方法　选择 1 4 9例服用拉咪呋啶用药 1年后 ,且 HBV DNA含量持续维持在较高水平或 DNA含量有反跳现象的乙型肝炎患者 ,留取服药前和服药 1年后的两份血清 ,分别作 YVDD、YIDD、HBV M的检测 ,同时设置 2 0例未服用拉咪呋啶乙型肝炎患者为对照组。结果　在实验组 1 4 9例中有 70 % YVDD或 YIDD阳性 ,对照组无 1例阳性。HBV M,在 1 4 9例中有 1 2 %发生了三种模式的转化。结论　乙型肝炎病毒 P基因 C区Objective To observe the efficacy of lamivudine on the treatment of hepatitis B and the relationship between its resistance and hepatitis B virus genic mutation.Methods A total of 149 patients with hepatitis B received lamivudine for one year.The serum levels of YVDD,YIDD,HBV M were detected fefore and after receiving lamivudine respectively.Twenty hepatitis B patients didn't receive lamivudine as controls.Results In experiment group,the positive rate of YVDD/YIDD was 70% in 149 patients and the HBV M modles in 12% of patients had been changed.Conclusion YMDD genic mutation of HBV is associated with lamivudine resistance.

关 键 词：基因突变 耐药性 乙型肝炎病毒 拉咪呋啶 药物治疗 药物敏感性试验 

分 类 号：R512.62[医药卫生—内科学] R969.4[医药卫生—临床医学]